MRC1 and cancer: The analysis of immunohistology of 82 patients with MMR defect in this study revealed that 67.1% (27/82 of inflamed pattern and 28/82 of immune excluded) of the patients may be responsive to the blockade of immune checkpoint in cancer therapy.